PTPRC and leukemia: Delay in leukemia development correlated with reduced proportion of engrafted GFP+B220+ LSCs in the mice (11.6% and 23.2% after treatment with anti-B220 MSN-DN versus free DN, respectively, 24 hours before transplantation)(Fig. 3C, Supplementary Fig. S4).